Welcome to our dedicated page for Neuberger Berman High Yield Strategies SEC filings (Ticker: NHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) filings page on Stock Titan is designed to organize the Fund’s regulatory information in one place, even though no specific SEC filings are listed in the current data set. As a diversified, closed-end management investment company focused on the high yield debt securities market, the Fund’s regulatory documents typically explain its investment policies, use of leverage, distribution practices and risk disclosures in more detail than brief news releases.
While the recent information available comes from press releases rather than SEC forms, those announcements reference key topics that are often discussed in formal filings, such as the Fund’s use of leverage through instruments like Mandatory Redeemable Preferred Shares and Floating Rate Senior Notes, its level distribution policy and its compliance with Section 19 of the Investment Company Act of 1940, as amended. They also include standard language noting that forward-looking statements involve risks and uncertainties related to market conditions, competition, regulation and operational factors.
On Stock Titan, when NHS regulatory filings are available from EDGAR, users can access documents such as annual and semi-annual reports or other required filings and use AI-powered tools to help interpret the information. These tools can highlight how the Fund describes its high yield debt strategy, leverage, distribution sources and risk factors, complementing what is already communicated through press releases about distributions, tender offers and leverage adjustments.
Investors interested in the Fund’s structure and policies can use this page to review its historical and future filings as they are added, alongside AI-generated explanations that summarize complex sections into more accessible language.
Neuberger High Yield Strategies Fund Inc. filed Post‑Effective Amendment No. 3 to its Form N-2 pursuant to Rule 462(d) to file exhibits; the amendment becomes effective immediately upon filing. The filing consists primarily of an index of exhibits and incorporation-by-reference statements.
The filing includes a Calculation of Filing Fee totaling $604,965, and reports the number of record holders as of February 1, 2026: 14 record holders for Common Stock and 1 for Preferred Stock (MRPS Series D). The fund restates routine undertakings, including a suspension condition if net asset value moves beyond specified thresholds.
Neuberger High Yield Strategies Fund Inc. is conducting a transferable rights offering to issue 10,463,948 shares of Common Stock upon exercise of Rights. One Right will be issued per outstanding share on the Record Date of March 23, 2026; three Rights are required to purchase one new share (1-for-3). The Rights expire at 5:00 PM Eastern on April 15, 2026 unless extended and are expected to trade under the symbol NHS RT.
The estimated Subscription Price shown is $6.84 (based on a 95% formula), with estimated gross proceeds of $71,573,404 and estimated net proceeds of approximately $68,418,335 after an estimated $650,000 of offering expenses and a Dealer Manager fee equal to 3.50% of the Subscription Price. Rights exercised are irrevocable; shares issued will not be record date stock for the Fund’s April 30, 2026 monthly distribution.
Neuberger High Yield Strategies Fund Inc. filed Post-Effective Amendment No. 2 to its Form N-2 under Rule 462(d) to furnish and file exhibits to its registration statement. The amendment becomes effective immediately upon filing and incorporates prior registration statement content by reference. The filing includes an exhibit index, a Calculation of Filing Fee Tables cross-reference, a Plan of Distribution incorporation by reference, an itemized schedule of expected issuance expenses totaling $604,965, and the number of record holders as of February 1, 2026 (14 record holders of common stock; 1 record holder of MRPS Series D). The amendment also restates the Fund’s undertakings, indemnification provisions, and identifies the locations of accounts and records.
Neuberger High Yield Strategies Fund Inc. files a base prospectus registering $167,633,695 of common stock and transferable subscription rights to issue shares and/or rights in one or more offerings. The Fund's NAV per share was $7.25 and the last reported NYSE American sale price was $7.58 (a 4.55% premium) as of February 19, 2026.
The Fund had 31,386,322 shares outstanding as of February 19, 2026. As of October 31, 2025, the Fund reported loans of $61,000,000 and Mandatory Redeemable Preferred Shares, Series D with an aggregate liquidation preference of $40,000,000, representing a total leverage ratio of 30.2%; the Series D MRPS mature on September 29, 2026.
Neuberger High Yield Strategies Fund Inc. received an updated ownership report on its common shares from First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation. The group reports beneficial ownership of 5,725,238 shares, representing 22.08% of the fund’s common stock.
The reporting persons have no sole or shared voting power over these shares but report shared dispositive power over all 5,725,238 shares. The position largely reflects holdings in unit investment trusts sponsored by First Trust Portfolios L.P., plus other investment vehicles and accounts advised by First Trust Advisors L.P.
The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the fund. Each reporting entity disclaims beneficial ownership of the shares identified.
Registrant submitted a Form N-CEN annual report template containing structured responses and partial data entries for an investment company identified by symbol NHS. The filing includes discrete line items for brokerage activity: aggregate brokerage commissions paid of $200 and affiliated broker‑dealer commissions of $0.
The form lists multiple Principal Transactions line items showing transaction values such as $90,891,725.81 and $302,802,399.48 among other per‑dealer amounts. Several sections remain as placeholders or N/A (for example, securities lending monthly averages marked N/A), and identifying fields (CIK, Fund name, addresses) are blank in the excerpt.
Neuberger High Yield Strategies Fund Inc. received an initial insider ownership report from portfolio manager Steven Richard Ruh. The Form 3 states that, as of 12/31/2025, no securities of the fund are beneficially owned. The filing is administrative in nature and does not report any purchases, sales, or derivative positions.
Neuberger High Yield Strategies Fund Inc. (NHS) reported a strong year for the 12 months ended October 31, 2025. The closed-end fund delivered a 9.03% total return on a net asset value (NAV) basis, outperforming its benchmark, the ICE BofA U.S. High Yield Constrained Index, which returned 8.03%. On a market price basis, the Fund returned 5.76% over the same period.
The Fund seeks high total return by investing primarily in high yield (below-investment-grade) debt, with a portfolio heavily concentrated in U.S. corporate bonds across sectors such as pipelines, commercial services, insurance, entertainment and energy. U.S. investments represented 118.7% of net assets, reflecting the impact of leverage.
Net assets applicable to common stockholders were $233.3 million, with 31,348,719 common shares outstanding and a NAV of $7.44 per share. The Fund paid $1.09 per share in distributions to common stockholders during the year, of which $0.58 per share is expected to be treated as return of capital for tax purposes. A stable monthly distribution of $0.0905 per share was in place at period end.
The Fund employs financial leverage through a $61.0 million secured revolving credit facility and $40.0 million of Mandatory Redeemable Preferred Shares, Series D, which can amplify both income and volatility. Management highlights ongoing focus on bottom-up credit research and issuer fundamentals while acknowledging risks from economic, rate, inflation and credit conditions.
Neuberger High Yield Strategies Fund Inc. updates its prospectus to reflect a corporate name change and portfolio management transitions.
Effective December 18, 2025, the Fund changed its name from Neuberger Berman High Yield Strategies Fund Inc. to Neuberger High Yield Strategies Fund Inc. Effective December 31, 2025, Joseph Lind will expand his role to Co-Head of Special Situations and will cease portfolio management responsibilities to the Fund on or about December 31, 2026. Also effective December 31, 2025, Steve Ruh will join as a co-portfolio manager alongside Mr. Lind and Christopher Kocinski. The prospectus language for the "Management of the Funds – Portfolio Managers" section is replaced to reflect these role changes.
Neuberger Berman High Yield Strategies Fund Inc. (NHS) received an amended Schedule 13G filing (Amendment No. 9) from First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation disclosing beneficial ownership of 5,463,038 common shares, representing 21.07% of the class, as of 09/30/2025.
The filing lists 0 shares with sole voting power and 0 shares with shared voting power, and 5,463,038 shares with shared dispositive power. The shares are held primarily across unit investment trusts and accounts associated with First Trust; voting for UIT-held shares is conducted by the trustee to mirror unaffiliated holders. The reporting persons state the position is held in the ordinary course of business and not for the purpose of changing or influencing control, and they disclaim beneficial ownership.